ExpreS2ion Biotech Holding AB (OMXSTO:EXPRS2) Financings
Financings
| Raise | Date | In US dollars |
|---|---|---|
| New shares on exercise of TO 13 warrants and directed issue to guarantor Announced: SEK 19.3M–SEK 32.4M · SEK 1.6 a share · Vator Securities +2 Dealers: Vator Securities, SCHMIDT Capital Advisors, APREA Partners Buyers: Vator Securities (guarantee undertaking totalling SEK 19.3 million); Alumni Capital; Tellus Equity AB; Leif Helth Jensen; John Haurum; Thomas Larsson Use of proceeds: Complete the ES2B-C001 Phase I study, strengthen licensing negotiations, platform and CMC development, and business development | Sep 14, 2026 | US$1.98M |
| New shares under put option agreement Announced: up to SEK 50M Buyers: Alumni Capital Limited (commitment of up to SEK 50,000,000 in equity financing over 24 months) | Sep 14, 2026 | US$5.12M |
| Rights offering of units consisting of new shares and warrants of series TO 13 Closed: SEK 31.8M raised · SEK 1.6 a unit · warrants of series TO 13 issued free of charge, exercisable at a price corresponding… · Schmidt Capital Advisors +1 Dealers: Schmidt Capital Advisors, Vator Securities Buyers: Bent U. Frandsen (part of board and management subscription commitments totalling approximately SEK 0.7 million) Insiders: Board members and management, including CEO Bent U. Frandsen, gave subscription commitments totalling approximately SEK 0.7 million, about 1.3 percent of the Rights Issue Use of proceeds: Continue executing the prioritised strategy and support the Company through the period leading up to the TO 13 warrant exercise window | May 4, 2026 | US$3.43M |